Amanda Rae Schwarzenbart

Amanda Schwarzenbart is an associate in the firm’s Business Law department and a member of its Life Sciences group. She represents both private and public companies as well as underwriters in a broad range of corporate financing transactions, including series stage financings and public equity raises. She has significant experience with public listings via initial public offerings and reverse mergers. Amanda also advises companies on a range of corporate governance matters, with particular emphasis on SEC compliance and listing rules for public companies.

During law school she served as an Articles Editor of Emory Law Journal, President of the Intellectual Property Law Society and Director and Treasurer of Student Legal Services. She also completed externships with Novelis Inc., The Coca-Cola Company, and Judge Timothy Batten, Sr., of the Northern District of Georgia.

Amanda’s recent experience includes, among others, representation of:

• Aura Biosciences, Inc. in its $75.6 million initial public offering, $75 million “at-the-market” offering, $80.4 million follow on offering and $99 million follow on offering
• PepGen Inc. in its $108 million initial public offering
• Candel Therapeutics, Inc. in its $72 million initial public offering and $75 million “at-the-market” offering
• Vaccitech plc (now Barinthus Biotherapeutics plc) in its $110.5 million initial public offering
• The underwriters in Excientia plc’s $510 million initial public offering
• The underwriters in Omega Therapeutics, Inc.’s $125.8 million initial public offering
• Compass Therapeutics, Inc. in its $117.5 million follow-on offering
• Relay Therapeutics, Inc. in its $230 million follow-on offering
• The underwriters in Silence Therapeutics’ $56.5 million follow-on offering of American Depositary Shares
• The underwriters in Riley Exploration Permian, Inc.’s $65.2 million primary and secondary public offering
• The underwriters in multiple “at-the-market” transaction programs, including those of Sera Prognostics, Inc., and Nautilus Biotechnology, Inc.
• Compass Therapeutics, Inc. in its $80.25 million PIPE financing
• Vascular Biogenics Ltd. in its reverse merger transaction with Notable Labs, Ltd.
• Graphite Bio, Inc. in its reverse merger transaction with Lenz Therapeutics, Inc. and related $53.5 million private placement
• Harpoon Therapeutics, Inc. in its sale to Merck & Co.
• Repertoire Immune Medicines in its $67 million Series AA financing and rights offering
• PepGen Inc. in its $112.5 Series B financing

Prior to joining Goodwin, Amanda began her legal career as an associate in the New York office of Davis Polk & Wardwell LLP, where she focused her practice on capital markets and mergers and acquisitions.

Author, “Coordination is Corruption: An Argument for the Regulation of Coordinated Issue Advocacy Under Campaign Finance Law,” Emory Law Journal, July 14, 2020